生化基因 BIIB 深 沪
等待开盘 06-26 09:30:00 美东时间
201.67
+2.080
+1.04%
华盛通- 最 高206.66
- 今 开201.63
- 成交量 75.20万股
- 最 低 194.74
- 昨 收 199.59
- 总市值 2944.38万
- 52周最高 206.66
- 市盈率 静 19.39
- 换手率 515.05%
- 52周最低 121.06
- 委 比 -6.12%
- 总股本 0.00亿
- 历史最高 468.55
- 量 比 0.61
- 振 幅 5.97%
- 历史最低 0.00
- 每 手 1
- 风险率 23.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This House of Representative Just Bought Up To $375K In Biogen Stock
Records from June 8, 2026 indicate that Representative Maria Elvira Salazar of ...
06-09 23:15
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and other stock views.
06-08 21:58
UCB and Biogen Report Late-Stage Lupus Trial Results for Experimental Drug
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial
06-01 16:40
Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
Evercore ISI Group Reinstates Outperform on Biogen
Evercore ISI Group analyst Umer Raffat reinstates Biogen (NASDAQ:BIIB) with a Outperform.
05-16 01:48
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.
05-08 23:31
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
04-18 02:20
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technology, expanding its pipeline.
04-07 20:54
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
04-06 18:40
Biogen Flags $34M R&D Charge to Hit Q1 Earnings by $0.19 Per Share
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on
04-06 18:34
